SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies ​in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging ‌criticism that Novo's studies had design flaws. Although the trials failed to show statistically significant slowing of cognitive decline in patients given the drug,‌ "we still think it was the right decision.

Astronomers have discovered an additional 100 new worlds in data collected by NASA's exoplanet-hunting spacecraft TESS, thanks to an innovative AI program.

In a new report, Doctors Without Borders says sexual violence is the ‘defining feature’ of the conflict in Sudan.